Facultad De Medicina, Benemérita Universidad Autónoma De Puebla , Puebla, Puebla, Mexico.
Instituto De Fisiología, Benemerita Universidad Autónoma De Puebla , Puebla, Puebla, Mexico.
Expert Opin Ther Pat. 2020 Jul;30(7):487-494. doi: 10.1080/13543776.2020.1767071. Epub 2020 May 20.
Due to the primary role of PD-1 and LAG-3 in regulating the immune response in tumors, there is a need to develop therapies focused on the inhibition of PD-1 and LAG-3 in order to improve the immune response in patients with cancer. The authors of US2018326054 patent propose a method to eradicate cancer by using bispecific anti-PD-1/LAG-3 antibodies.
The US2018326054 patent describes anti-PD-1/LAG3 antibodies, pharmaceutical composition that contains it, and their application for cancer treatment, particularly pancreatic carcinoma. Proof concept and preclinical results show anti-PD-1/LAG-3 bispecific antibodies bind and are internalized by CD4 + T cells thereby increasing their effector functions (release of Granzyme B and INF-γ) in the presence of tumor cells, and completely suppress tumors in a murine model.
Anti-PD-1/LAG-3 bispecific antibodies of the US2018326054 patent are new in a general concept, but treatment data is only shown for pancreatic carcinoma. The results to be obtained in future clinical trials of safety and efficacy could conclude whether these bispecific anti-PD-1/LAG-3 antibodies will be useful in a cancer treatment scheme.
由于 PD-1 和 LAG-3 在调节肿瘤中的免疫反应方面起着主要作用，因此需要开发专注于抑制 PD-1 和 LAG-3 的疗法，以提高癌症患者的免疫反应。美国专利号 2018326054 的作者提出了一种使用双特异性抗 PD-1/LAG-3 抗体来消灭癌症的方法。
美国专利号 2018326054 描述了抗 PD-1/LAG3 抗体、含有它的药物组合物及其在癌症治疗中的应用，特别是胰腺癌。概念验证和临床前结果表明，抗 PD-1/LAG-3 双特异性抗体与 CD4+T 细胞结合并被其内化，从而在存在肿瘤细胞的情况下增强其效应功能（Granzyme B 和 INF-γ 的释放），并在小鼠模型中完全抑制肿瘤。
美国专利号 2018326054 中的抗 PD-1/LAG-3 双特异性抗体在一般概念上是新颖的，但仅显示了胰腺癌的治疗数据。未来关于安全性和疗效的临床试验的结果将可以确定这些双特异性抗 PD-1/LAG-3 抗体是否将对癌症治疗方案有用。
